| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
139,126,000 |
| Market
Cap: |
147.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.8871 - $4.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile bluebird bio is a company focused on the pursuit of curative gene therapies for severe genetic diseases. Co. has late-stage clinical and research programs for the treatment of sickle cell disease (SCD), ss-thalassemia and cerebral adrenoleukodystrophy and is developing research to apply new technologies to these and other diseases. Using a proprietary lentiviral vector platform, Co. custom designs each of its therapies to address the underlying cause of disease by introducing a functional copy of a gene to patients' own isolated hematopoietic stem cells. Co. is developing lovotibeglogene autotemcel as a one-time treatment for patients with SCD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
17,438 |
35,533 |
57,514 |
116,582 |
| Total Sell Value |
$26,639 |
$61,294 |
$139,194 |
$443,003 |
| Total People Sold |
3 |
5 |
5 |
9 |
| Total Sell Transactions |
3 |
9 |
12 |
23 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Davidson David |
Chief Medical Officer |
• – – |
2019-07-05 |
4 |
OE |
$5.50 |
$372,053 |
D/D |
7,660 |
39,276 |
|
- |
|
| Walsh Jeffrey T. |
Chief Strategy Officer |
• – – |
2019-06-18 |
4 |
AS |
$126.12 |
$12,612 |
D/D |
(100) |
40,921 |
|
- |
|
| Walsh Jeffrey T. |
Chief Strategy Officer |
• – – |
2019-06-18 |
4 |
OE |
$24.47 |
$2,447 |
D/D |
100 |
41,021 |
|
- |
|
| Walsh Jeffrey T. |
Chief Strategy Officer |
• – – |
2019-06-10 |
4 |
AS |
$125.19 |
$175,619 |
D/D |
(1,400) |
40,921 |
|
- |
|
| Walsh Jeffrey T. |
Chief Strategy Officer |
• – – |
2019-06-10 |
4 |
OE |
$24.47 |
$34,258 |
D/D |
1,400 |
42,321 |
|
- |
|
| Melton Douglas |
Director |
– • – |
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
4,700 |
|
- |
|
| Lynch Daniel |
Director |
– • – |
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,400 |
5,600 |
|
- |
|
| Vachon Mark |
Director |
– • – |
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
2,000 |
|
- |
|
| Schenkein David P |
Director |
– • – |
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
5,176 |
|
- |
|
| Davidson David |
Chief Medical Officer |
• – – |
2019-06-06 |
4 |
AS |
$121.68 |
$620,539 |
D/D |
(5,060) |
31,616 |
|
- |
|
| Davidson David |
Chief Medical Officer |
• – – |
2019-06-06 |
4 |
OE |
$50.51 |
$255,581 |
D/D |
5,060 |
36,676 |
|
- |
|
| Agwunobi John O |
Director |
– • – |
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
4,700 |
|
- |
|
| Dixon Wendy L |
Director |
– • – |
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
4,000 |
|
- |
|
| Gregory Philip D |
Chief Scientific Officer |
• – – |
2019-06-05 |
4 |
AS |
$127.54 |
$231,488 |
D/D |
(1,800) |
31,092 |
|
- |
|
| Gregory Philip D |
Chief Scientific Officer |
• – – |
2019-06-05 |
4 |
OE |
$50.51 |
$83,226 |
D/D |
1,300 |
32,892 |
|
- |
|
| Wentworth Kory James |
Principal Accounting Officer |
• – – |
2019-06-05 |
4 |
S |
$126.11 |
$7,784 |
D/D |
(61) |
6,846 |
|
- |
|
| Wentworth Kory James |
Principal Accounting Officer |
• – – |
2019-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
212 |
6,907 |
|
- |
|
| Walsh Jeffrey T. |
Chief Strategy Officer |
• – – |
2019-05-10 |
4 |
AS |
$131.11 |
$198,450 |
D/D |
(1,500) |
40,921 |
|
- |
|
| Walsh Jeffrey T. |
Chief Strategy Officer |
• – – |
2019-05-10 |
4 |
OE |
$24.47 |
$36,705 |
D/D |
1,500 |
42,421 |
|
- |
|
| Cole Jason |
Chief Operating andLegal Offic |
• – – |
2019-05-10 |
4 |
OE |
$50.51 |
$28,387 |
D/D |
562 |
27,006 |
|
- |
|
| Davidson David |
Chief Medical Officer |
• – – |
2019-05-06 |
4 |
AS |
$138.25 |
$883,718 |
D/D |
(6,360) |
31,616 |
|
- |
|
| Davidson David |
Chief Medical Officer |
• – – |
2019-05-06 |
4 |
OE |
$5.50 |
$34,983 |
D/D |
6,360 |
37,976 |
|
- |
|
| Gregory Philip D |
Chief Scientific Officer |
• – – |
2019-05-06 |
4 |
AS |
$138.19 |
$249,183 |
D/D |
(1,800) |
31,592 |
|
- |
|
| Gregory Philip D |
Chief Scientific Officer |
• – – |
2019-05-06 |
4 |
OE |
$50.51 |
$83,226 |
D/D |
1,300 |
33,392 |
|
- |
|
| Walsh Jeffrey T. |
Chief Strategy Officer |
• – – |
2019-04-10 |
4 |
AS |
$156.44 |
$234,976 |
D/D |
(1,500) |
40,921 |
|
- |
|
939 Records found
|
|
Page 11 of 38 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.06 (5.36%) 
